Pancreatic cancer
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Who can joinAdults
Age18+ years
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Where to go
5 hospitals in India taking patients for this trial.
Tata Memorial HospitalMumbai, MaharashtraDirections ↗
Venkateshwar HospitalNew Delhi, National Capital Territory of DelhiDirections ↗
Rajiv Gandhi Cancer Institute And Research CentreNew Delhi, National Capital Territory of DelhiDirections ↗
Sawai Man Singh Medical College Hospital (SMS Hospital)Jaipur, RajasthanDirections ↗
Chittaranjan National Cancer InstituteKolkata, West BengalDirections ↗
Registry summary (technical)
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.
Sponsor: Pfizer
NCT06989437 on ClinicalTrials.gov
Last updated on the registry 14 Oct 2026 · read by us 20 Oct 2026